Commentary on “Nephrectomy and High-Salt Diet Inducing Pulmonary Hypertension and Kidney Damage by Increasing Ang II Concentration in Rats”

Author Contributions

S.-F.L.: Writing—original draft; N.Z.: Supervision, Writing and Revising—review & editing.

Ethics Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Not applicable.

Funding

This research received no external funding.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Statement of the Use of AI Tools

During the writing of this manuscript, the authors utilized generative AI tools (such as ChatGPT and DeepL) in order to improve readability and language. All conceptual development and final content decisions were made independently by the authors. After using these tools, the authors reviewed and edited the content as needed and took full responsibility for the content of the published article.

References

[1] Jiang Q, Yang Q, Zhang C, Hou C, Hong W, Du M, et al. Nephrectomy and high-salt diet inducing pulmonary hypertension and kidney damage by increasing Ang II concentration in rats. Respir. Res. 2024, 25, 288.

[2] Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur. Respir. J. 2023, 61, 2200879.

[3] Kovacs G, Bartolome S, Denton CP, Gatzoulis MA, Gu S, Khanna D, et al. Definition, classification and diagnosis of pulmonary hypertension. Eur. Respir. J. 2024, 64, 2401324.

[4] Navaneethan SD, Wehbe E, Heresi GA, Gaur V, Minai OA, Arrigain S, et al. Presence and outcomes of kidney disease in patients with pulmonary hypertension. Clin. J. Am. Soc. Nephrol. 2014, 9, 855-863.

[5] Wang L, Zhang W, Zhang C, Yan Z, Li S, Zhang C, et al. Prognostic effect of pulmonary hypertension in patients with chronic kidney disease: Univariate and multivariate analyses of factors associated with survival. Front. Med. 2022, 9, 972937.

[6] Travers A, Farber HW, Sarnak MJ. Pulmonary Hypertension in Chronic Kidney Disease. Cardiol. Clin. 2021, 39, 427-434.

[7] Sise ME, Courtwright AM, Channick RN. Pulmonary hypertension in patients with chronic and end-stage kidney disease. Kidney Int. 2013, 84, 682-692.

[8] Lin C, Ge Q, Wang L, Zeng P, Huang M, Li D. Predictors, prevalence and prognostic role of pulmonary hypertension in patients with chronic kidney disease: a systematic review and meta-analysis. Ren. Fail. 2024, 46, 2368082.

[9] Adam RJ, Williams AC, Kriegel AJ. Comparison of the surgical resection and infarct 5/6 nephrectomy rat models of chronic kidney disease. Am. J. Physiol. Renal Physiol. 2022, 322, F639-F654.

[10] Yang Q, Su S, Luo N, Cao G. Adenine-induced animal model of chronic kidney disease: current applications and future perspectives. Ren. Fail. 2024, 46, 2336128.

[11] Pacurari M, Kafoury R, Tchounwou PB, Ndebele K. The Renin-Angiotensin-aldosterone system in vascular inflammation and remodeling. Int. J. Inflam. 2014, 2014, 689360.

[12] Vaillancourt M, Chia P, Sarji S, Nguyen J, Hoftman N, Ruffenach G, et al. Autonomic nervous system involvement in pulmonary arterial hypertension. Respir. Res. 2017, 18, 201.

[13] Kuba K, Imai Y, Penninger JM. Angiotensin-converting enzyme 2 in lung diseases. Curr. Opin. Pharmacol. 2006, 6, 271-276.

[14] Shenoy V, Qi Y, Katovich MJ, Raizada MK. ACE2, a promising therapeutic target for pulmonary hypertension. Curr. Opin. Pharmacol. 2011, 11, 150-155.

[15] Guignabert C, de Man F, Lombes M. ACE2 as therapy for pulmonary arterial hypertension: the good outweighs the bad. Eur. Respir. J. 2018, 51, 1800848.

[16] Shen H, Zhang J, Wang C, Jain PP, Xiong M, Shi X, et al. MDM2-Mediated Ubiquitination of Angiotensin-Converting Enzyme 2 Contributes to the Development of Pulmonary Arterial Hypertension. Circulation 2020, 142, 1190-1204.

[17] Hu HH, Zhang RF, Dong LL, Chen EG, Ying KJ. Overexpression of ACE 2 prevents hypoxia-induced pulmonary hypertension in rats by inhibiting proliferation and immigration of PASMCs. Eur. Rev. Med. Pharmacol. Sci. 2020, 24, 3968-3980.

[18] Bollag WB. Regulation of aldosterone synthesis and secretion. Compr. Physiol. 2014, 4, 1017-1055.

[19] Chaumais MC, Djessas MRA, Thuillet R, Cumont A, Tu L, Hebert G, et al. Additive protective effects of sacubitril/valsartan and bosentan on vascular remodelling in experimental pulmonary hypertension. Cardiovasc. Res. 2021, 117, 1391-1401.

[20] Hong J, Arneson D, Umar S, Ruffenach G, Cunningham CM, Ahn IS, et al. Single-Cell Study of Two Rat Models of Pulmonary Arterial Hypertension Reveals Connections to Human Pathobiology and Drug Repositioning. Am. J. Respir. Crit. Care Med. 2021, 203, 1006-1022.

[21] Gembillo G, Calimeri S, Tranchida V, Silipigni S, Vella D, Ferrara D, et al. Lung Dysfunction and Chronic Kidney Disease: A Complex Network of Multiple Interactions. J. Pers. Med. 2023, 13, 286.

[22] Chemla D, Castelain V, Herve P, Lecarpentier Y, Brimioulle S. Haemodynamic evaluation of pulmonary hypertension. Eur. Respir. J. 2002, 20, 1314-1331.

[23] Thenappan T, Prins KW, Pritzker MR, Scandurra J, Volmers K, Weir EK. The Critical Role of Pulmonary Arterial Compliance in Pulmonary Hypertension. Ann. Am. Thorac. Soc. 2016, 13, 276-284.

[24] Tamulenaite E, Zvirblyte R, Ereminiene R, Ziginskiene E, Ereminiene E. Changes of Left and Right Ventricle Mechanics and Function in Patients with End-Stage Renal Disease Undergoing Haemodialysis. Medicina 2018, 54, 87.

[25] Speer T, Dimmeler S, Schunk SJ, Fliser D, Ridker PM. Targeting innate immunity-driven inflammation in CKD and cardiovascular disease. Nat. Rev. Nephrol. 2022, 18, 762-778.

[26] Daenen K, Andries A, Mekahli D, Van Schepdael A, Jouret F, Bammens B. Oxidative stress in chronic kidney disease. Pediatr. Nephrol. 2019, 34, 975-991.

[27] Wang B, Li ZL, Zhang YL, Wen Y, Gao YM, Liu BC. Hypoxia and chronic kidney disease. EBioMedicine 2022, 77, 103942.

[28] Ding N, Lv Y, Su H, Wang Z, Kong X, Zhen J, et al. Vascular calcification in CKD: New insights into its mechanisms. J. Cell. Physiol. 2023, 238, 1160-1182.

[29] Sun Y, Sangam S, Guo Q, Wang J, Tang H, Black SM, et al. Sex Differences, Estrogen Metabolism and Signaling in the Development of Pulmonary Arterial Hypertension. Front. Cardiovasc. Med. 2021, 8, 719058.

[30] Rossi GP, Caroccia B, Seccia TM. Role of estrogen receptors in modulating aldosterone biosynthesis and blood pressure. Steroids 2019, 152, 108486.